Leech Thrombomodulin-binding factor
Modulates the thrombin-thrombomodulin axis — implications for protein C pathway.
- Hementerin80 kDa
- Hementin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- Leech Thrombomodulin-binding factor11 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Purified natural compound
- Safety domains
- Bleeding
Clinical translation limit
The reported thrombomodulin-binding activity is mechanistic only and does NOT establish clinical anticoagulant efficacy. No FDA-approved derivative exists; distinct from recombinant human thrombomodulin (ART-123/thrombomodulin alfa) developed by Asahi Kasei for DIC.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Molecular weight
- 11,000 Da
- Source species
- Hirudo medicinalis
Biological Targets
- → thrombomodulin / thrombin / Protein C axis
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor from the Mexican leech (1987) — used in early animal studies of factor Xa as a target; the DOAC drugs are synthetic and not derived from it.
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.